Evaluation of anti-androgen therapy in a panel of prostate patient-derived xenograft models
Jason Davies, Nektaria Papadopoulou, Louise Wainwright, Anthony Oakden, Chira Roberts, Jane Wrigley, Jason King, Anne Collins*, Wubin Qian, Likun Zhang, Bin Fan, Davy Ouyang, Jie Cai, and Rajendra Kumari
*University of York, York, UK
Prostate cancer is a complex disease, with multiple stages that need to be accurately recapitulated in the preclinical setting. A lack of prostate cancer models which fully represent the benign, latent, aggressive, and metastatic forms of human disease has hampered preclinical research and new drug development.
Patient-derived xenografts (PDX) are known to be more clinically relevant than conventional cell line derived alternatives, providing a new preclinical modelling option. We have developed and validated a panel of prostate cancer PDX models for preclinical studies.
This poster details hormone sensitive and castrate resistant prostate cancer (CRPC) PDX model characterization by H&E staining, immunohistochemistry, and RNAseq, as well as standard of care and new hormonal agent treatment data.
Read this Poster to Discover:
- A well characterized panel of hormone sensitive and CRPC prostate cancer PDX models for predictive preclinical drug development
- That the PDX models retain the structure of parental tumours, and expression levels of AR and PSA
- Varied response and resistance to docetaxel, enzalutamide, and abiraterone across the panel of prostate cancer PDX models